(UroToday.com) The first prostate cancer session at the 2020 Society of Urologic Oncology (SUO) Annual Virtual Meeting highlighted a talk on radiogenomics by Dr. Robert Reiter from the University of California Los Angeles Geffen School of Medicine. Dr. Reiter started his presentation by presenting a case of a 63-year-old African American man with a prostate-specific antigen (PSA) […]
(UroToday.com) In a point and counterpoint format at the 2020 Society of Urologic Oncology (SUO) Annual Virtual Meeting discussing whether prostate-specific membrane antigen (PSMA) PET-CT is ready for prime-time use, Dr. Matthew Cooperberg took the counterpoint approach that PSMA PET-CT is not yet ready for prime-time use.
(UroToday.com) Standard or high dose chemotherapy has curative potential in relapsed patients with germ cell tumor but is associated with significant toxicity. Although cisplatin-based induction chemotherapy is effective in treating metastatic testicular cancer, approximately 30% of patients will require salvage chemotherapy or surgery. Patients with platinum-refractory disease who can potentially be cured with salvage retroperitoneal lymph […]
(UroToday.com) At the 2020 Society of Urologic Oncology (SUO) Annual Virtual Meeting, Dr. Neal Shore chaired a session examining the use of newer and emerging agents in bladder cancer, which highlighted a presentation by medical oncologist Dr. Robert Dreicer discussing novel treatment options for patients with advanced bladder cancer. Dr. Dreicer notes that in 1993 cisplatin […]
(UroToday.com) The Society of Urologic Oncology (SUO) President, Dr. Michael Cookson, started this presentation of the Joseph A. Smith, Jr. Mentorship Lecture by highlighting the importance of mentoring, quoting Winston Churchill, “We make a living by what we get, but we make a life by what we give.” He then quoted President John F. Kennedy, […]
(UroToday.com) The 2020 Society of Urologic Oncology (SUO) Annual Virtual Meeting prostate cancer session included a presentation from Dr. Thomas Fuchs who discussed aspects of computer-assisted pathological diagnosis for prostate cancer. Dr. Fuchs notes that much work in this space has occurred at the Warren Alpert Center for Digital and Computational Pathology at the Memorial Sloan […]
Assessing genetic lifetime risk for prostate cancer has been proposed as a means of risk stratification to identify those for whom prostate-specific antigen (PSA) testing is likely to be most valuable.
Testicular type II germ cell tumours (GCTs) are an exemplar of a curable cancer and the most common malignancy in males aged ≤35 years. Even in metastatic stages, about 70% of patients can be cured by cisplatin-based chemotherapy and multimodal treatments.
Perinephric fat invasion (PFI) is a key component of renal cell carcinoma (RCC) staging, but there is limited data pertaining to biopsy tract seeding (BTS), resulting in perirenal tissue involvement (BTS-P).
Papillary renal carcinoma (PRCC) is one of the important subtypes of kidney cancer, with a high degree of heterogeneity. At present, there is still a lack of robust and accurate biomarkers for the diagnosis, prognosis and treatment selection of PRCC.
